Loading...
Loading...
CADL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 8.1M |
| Operating I/L | -8.1M |
| Other Income/Expense | 3.0M |
| Interest Income | -0.7M |
| Pretax | -5.1M |
| Income Tax Expense | -15.7M |
| Net Income/Loss | 10.7M |
Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company specializing in the development of immunotherapies for cancer patients. The company's lead product, CAN-2409, is undergoing Phase II clinical trials for pancreatic cancer, Phase III trials for prostate cancer, and Phase II trials for lung cancer, with completed Phase Ib/II trials for high-grade glioma treatment. Additionally, the company is developing CAN-3110, currently in Phase I trials for recurrent glioblastoma. Candel Therapeutics, Inc. generates revenue through the development and commercialization of these innovative immunotherapies for various cancer indications.
